ResearcherErasmus MCActive in the last 2 years
Marcella Willemsen
Matched on ORCID iD 0000-0003-3376-6734; OpenAlex author ID A5025168772. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 22
2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper
Papers 6
- REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Co-author DOI 10.1038/s41467-025-66092-1↗
- FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction. Last author DOI 10.1016/j.ejca.2023.113440↗
- Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. Last author DOI 10.1158/1078-0432.ccr-23-4085↗
- Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer. First author DOI 10.1200/jco.23.02585↗
- B cell immune profiles in dysbiotic vermiform appendixes of pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2023.1230306↗
- Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced P… Co-author DOI 10.3390/cancers14215299↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Casper H.J. van Eijck · 6 shared papers, 2022–2025 · strength 1.06
- Paper Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. DOI 10.1158/1078-0432.ccr-23-4085↗
- Paper FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination th… DOI 10.1016/j.ejca.2023.113440↗
- Paper REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in meta… DOI 10.1038/s41467-025-66092-1↗
- Casper W.F. van Eijck · 3 shared papers, 2024–2025 · strength 0.61
- Paper Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. DOI 10.1158/1078-0432.ccr-23-4085↗
- Paper FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination th… DOI 10.1016/j.ejca.2023.113440↗
- Paper REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in meta… DOI 10.1038/s41467-025-66092-1↗
- Dana A. M. Mustafa · 3 shared papers, 2022–2024 · strength 0.56
- Paper Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. DOI 10.1158/1078-0432.ccr-23-4085↗
- Paper FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination th… DOI 10.1016/j.ejca.2023.113440↗
- Paper Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-… DOI 10.3390/cancers14215299↗
- Freek R. van ‘t Land · 3 shared papers, 2022–2025 · strength 0.49
- Paper REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in meta… DOI 10.1038/s41467-025-66092-1↗
- Paper Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer. DOI 10.1200/jco.23.02585↗
- Paper Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-… DOI 10.3390/cancers14215299↗
- Songul Kucukcelebi · 2 shared papers, 2024–2025 · strength 0.40
- Paper Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. DOI 10.1158/1078-0432.ccr-23-4085↗
- Paper REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in meta… DOI 10.1038/s41467-025-66092-1↗
- Michail Doukas · 2 shared papers, 2024–2025 · strength 0.36
- Eveline E. Vietsch · 2 shared papers, 2023–2024 · strength 0.35
- Hassana el Haddaoui · 1 shared paper, 2024 · strength 0.22
- Fleur van der Sijde · 1 shared paper, 2024 · strength 0.21
- Gaby J. Strijk · 1 shared paper, 2024 · strength 0.21
- Judith de Vos‐Geelen · 1 shared paper, 2025 · strength 0.18
- Aniek E. van Diepen · 1 shared paper, 2025 · strength 0.18
- Ferry A.L.M. Eskens · 1 shared paper, 2025 · strength 0.18
- Marjolein Y.V. Homs · 1 shared paper, 2025 · strength 0.18
- Noel F.C.C. de Miranda · 1 shared paper, 2023 · strength 0.14
- Peter D. Katsikis · 1 shared paper, 2023 · strength 0.14
- Ricki T. Krog · 1 shared paper, 2023 · strength 0.14
- Bas Groot Koerkamp · 1 shared paper, 2023 · strength 0.14
- Roeland F. de Wilde · 1 shared paper, 2023 · strength 0.14
- Willem de Koning · 1 shared paper, 2022 · strength 0.13
- Sai Ping Lau · 1 shared paper, 2022 · strength 0.13
- Joost J.M.E. Nuyttens · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.